SIU 2017: Venous Tumor Thrombus in Patients with Renal Cell Carcinoma - Clinical and Oncological Outcome after Surgery
Lisbon, Portugal (UroToday.com) Renal cell carcinoma (RCC) is associated with intravascular tumor thrombus in 4%-10% of cases, of which nearly 1/3 of patients also have concurrent metastatic disease. The authors evaluated the clinical outcome and factors affecting survival in patients with RCC and venous tumor thrombus (VTT) in their center.
SIU 2017: Local Ischemia as an Alternative to Thermal in Kidney Resection
Lisbon, Portugal (UroToday.com) Partial nephrectomy in renal cell carcinoma provides good overall survival, but the use of central ischemia that promotes radical removal of the tumor and adequate hemostasis leads to irreversible changes in the kidneys that can lead to loss of function and possibly to the development of chronic renal failure. The authors aimed to evaluate the effectiveness of local ischemia rather than central ischemia during partial nephrectomy and assess its impact on kidney function.
SIU 2017: Non-Androgen-Receptor-Targeted Options for mCRPC
Lisbon, Portugal (UroToday.com) The CHAARTED and STAMPEDE studies demonstrated that administration of Docetaxel in metastatic hormone sensitive prostate cancer (mHSPC) reduced the risk of death by 39%, creating a trend of giving these advanced lines of treatment earlier than in the past. Dr. Saad therefore asks the following question: Since androgen deprivation therapy (ADT) is the standard first line treatment of metastatic castrate resistant prostate cancer (mCRPC), is chemotherapy effective after hormonal therapy? The COU-AA-302 study examined this question by administration of docetaxel post abiraterone, and demonstrating a PSA fall by 50% in almost 50% of the patients. Another study – TROPIC, analyzed administration of Cabazitaxel after docetaxel and compared it to mitoxantrone. This study also had positive results with increase of overall survival by a median of 2.4 months.
SIU 2017: Role of Cytoreductive Surgery in CRPC
Lisbon, Portugal (UroToday.com) There has been a paradigm shift in several solid tumors, emphasizing locoregional treatment in the presence of metastatic disease. The question Dr. Hammerer raises in this presentation is whether local therapy should be performed in CRPC men or/and men with oligometastatic disease with a rising PSA on androgen deprivation therapy (ADT).
SIU 2017: Advances in Imaging in CRPC: New Ligands for Pet Imaging
Lisbon, Portugal (UroToday.com) Small molecules serving as optimal tracers for molecular imaging must have several properties to be considered a good tracer. These include high specificity for receptors, fast circulation through the body, fast clearance, easy to produce and label, high stability and to not trigger a host immune response.
SIU 2017: Optimal Sequencing and Monitoring of Androgen Receptor (AR) Pathway Inhibitors in mCRPC
Lisbon, Portugal (UroToday.com) Dr. Gleave began his presentation with the fact that in hormone naïve prostate cancer, it has recently been shown in the STAMPEDE and LATITUDE trials that Abiraterone and prednisone was a well-tolerated treatment. Furthermore it improved overall survival by 37%, failure free survival by 70%, and symptomatic skeletal events by 30%-55%. These studies have demonstrated that abiraterone and prednisone should be the standard of care for men starting long term ADT.
SIU 2017: Mechanisms of Treatment Induced Resistance
Lisbon, Portugal (UroToday.com) Dr. Evans gave an elaborate talk on the various mechanisms of treatment induced resistance in castrate resistant prostate cancer (CRPC). He began his talk by describing the many potential targets for treatment in the androgen axis, and resistance mechanisms. These include androgen receptor (AR) mutations, loss of AR, AR DNA binding, CYP17A1 expression, and more.